Gefitinib (Iressa®): a novel treatment for non-small cell lung cancer
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2004/02/01
-
Indian UGC (journal)
-
Refrences31
-
Citations42
-
Johan F Vansteenkiste
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Expression of constitutively activated EGFRvlll in non‐small cell lung cancer | Cancer Science |
| 96 | 2003 |
| 10.1016/S0169-5002(02)00308-2 | 2003 | |||
| 10.1056/NEJMoa011954 | 2002 | |||
| Gefitinib | Drugs |
| 48 | 2002 |
| 10.1200/JCO.2001.19.13.3210 | 2001 |
Refrences Analysis
| Category | Category Repetition |
|---|---|
| Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens | 7 |
| Medicine: Medicine (General) | 3 |
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 7
is the most frequently represented among the references in this article. It primarily includes studies from Cancer Research and Cancer Science. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3‐d]pyrimidine derivatives as EGFR inhibitors | Drug Development Research |
| 2 | 2023 |
Anticancer perspective of 6-shogaol: anticancer properties, mechanism of action, synergism and delivery system | Chinese Medicine |
| 2 | 2023 |
Recent Trends in Rationally Designed Molecules as Kinase Inhibitors | Current Medicinal Chemistry |
| 4 | 2023 |
Gefitinib: An Updated Review of its Role in the Cancer Management, its
Nanotechnological Interventions, Recent Patents and Clinical Trials | Recent Patents on Anti-Cancer Drug Discovery |
| 11 | 2023 |
6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells | International Journal of Molecular Sciences |
| 5 | 2023 |
Citations Analysis
The category
Science: Chemistry 20
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Pyrazolyl–benzoxazole derivatives as protein kinase inhibitors. Design and validation of a combinatorial library and was published in 2005. The most recent citation comes from a 2023 study titled Anticancer perspective of 6-shogaol: anticancer properties, mechanism of action, synergism and delivery system. This article reached its peak citation in 2018, with 7 citations. It has been cited in 28 different journals, 17% of which are open access. Among related journals, the Bioorganic Chemistry cited this research the most, with 6 citations. The chart below illustrates the annual citation trends for this article.